ArticleUrologic oncology2016
Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.
Article in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- Sociodemographic trends in prostate cancer: insights from the All of Us Research Program.JNCI cancer spectrum · 2026Article
- Patient-Provider Communication and Treatment Decision-Making among Latino Men with Prostate Cancer: A Qualitative Study.Journal of racial and ethnic health disparities · 2026Article
- Article
- Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Prostate Cancer Disparities in Clinical Characteristics and Survival among Black and Latino Patients Considering Nativity: Findings from the California Cancer Registry.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Article
- Race-specific prostate cancer outcomes in a cohort of low and favorable-intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017.Cancer medicine · 2022Article
- Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.Frontiers in oncology · 2021Review
- Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.Journal of racial and ethnic health disparities · 2019Article
- Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation.International urology and nephrology · 2019Article
- Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis.Prostate cancer and prostatic diseases · 2019Article
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.Prostate cancer and prostatic diseases · 2019Article
- Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?Clinical genitourinary cancer · 2018Article
- Racial disparities and considerations for active surveillance of prostate cancer.Translational andrology and urology · 2018Review
- Article
- Emotional Distress Increases the Likelihood of Undergoing Surgery among Men with Localized Prostate Cancer.The Journal of urology · 2017Article
- Racial Differences in Prostate Cancer Treatment: The Role of Socioeconomic Status.Ethnicity & disease · 2017Article
- Racial Differences in the Diagnosis and Treatment of Prostate Cancer.International neurourology journal · 2016Review
- Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveAfrican-American (AA) men have excess mortality from prostate cancer compared with White men, which has remained unchanged over several decades. The purpose of this study is to determine if race/ethnicity is an independent predictor of receipt of any definitive treatment vs. watchful waiting/active surveillance (WW/AS). METHODS AND MATERIALS: Men diagnosed with prostate cancer from 2004 to 2011 were identified from the Surveillance, Epidemiology, and End-Results program. Multinomial logistic regression analysis was performed to determine the relative risk ratio (RRR) of receipt of radical prostatectomy (RP), external beam radiation therapy (RT), brachytherapy, cryotherapy, or combination therapy vs. WW/AS.
resultsCompared with White men, AA men were significantly less likely to receive RP (RRR = 0.53, P<0.001), brachytherapy (RRR = 0.72, P<0.001), cryotherapy (RRR = 0.84, P = 0.001), and combination therapy (RRR = 0.70, P<0.001), and more likely to receive RT (RRR = 1.03, P = 0.041) vs. AS/WW. Hispanic men were significantly less likely to receive RP (RRR = 0.84, P<0.001) and brachytherapy (RRR = 0.77, P<0.001), and more likely to receive RT (RRR = 1.08, P<0.001), and cryotherapy (RRR = 1.19, P = 0.005) vs. AS/WW compared with White men.
conclusionsThe disparate risk of receiving definitive treatment among AA and Hispanic men represents a significant public health issue that requires efforts to improve physician education, increase cultural competency, and ensure equitable access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.